[stock_market_widget type="clock-markets" template="analog" timezone="America/New_York" title="New York" style="font-size: 7px; width: 100px;"] [stock_market_widget type="clock-markets" template="analog" timezone="Europe/London" title="London" style="font-size: 7px; width: 100px;"] [stock_market_widget type="clock-markets" template="analog" timezone="Europe/Brussels" title="Brussels" style="font-size: 7px; width: 100px;"] [stock_market_widget type="clock-markets" template="analog" timezone="Asia/Hong_Kong" title="Hong Kong" style="font-size: 7px; width: 100px;"] [stock_market_widget type="clock-markets" template="analog" timezone="Asia/Tokyo" title="Tokyo" style="font-size: 7px; width: 100px;"] [stock_market_widget type="clock-markets" template="analog" timezone="Australia/Sydney" title="Sydney" style="font-size: 7px; width: 100px;"]

Stock Market News

U.S. FDA advisers back authorization of Moderna COVID vaccine for ages 6-17

06/14/2022

Less than a minute

2022.06.14 23:51

U.S. FDA advisers back authorization of Moderna COVID vaccine for ages 6-17
FILE PHOTO: Test tubes are seen in front of a displayed Moderna logo in this illustration taken, May 21, 2021. REUTERS/Dado Ruvic/Illustration/File Photo

(Reuters) – Advisers to the U.S. Food and Drug Administration on Tuesday recommended the authorization of Moderna (NASDAQ:MRNA) Inc’s COVID-19 vaccine for children and teens aged 6 to 17 years of age.

Source

06/14/2022

Less than a minute